SUPERNUS PHARMACEUTICALS INC

SUPERNUS PHARMACEUTICALS INC Action · US8684591089 · SUPN · A1JX3U (XNMS) — cotations en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Aperçu
Analyse alimentée par l’IA
Analyse fondamentale
Découvrez ce que disent vraiment les chiffres — avant le marché
Analyser maintenant
Sentiment des actualités
Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?
Analyser maintenant
Acheter / Conserver / Vendre
Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.
Analyser maintenant
Évaluation des risques
Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.
Analyser maintenant
Juste valeur
Cette action est-elle bon marché, correctement valorisée ou surévaluée ?
Analyser maintenant
Dernières analyses d’IA sur SUPERNUS PHARMACEUTICALS INC
Résumé de la Note des Analystes
gauge-img
Achat
Achat fort
Achat
Conserver
Vente
Vente forte
0
9
5
0
0
Pas de cours
01.05.2026 20:37
Cours actuels de SUPERNUS PHARMACEUTICALS INC
BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
SUPN
USD
01.05.2026 20:37
47,85 USD
-0,15 USD
-0,31 %
IEXG: IEX
IEX
SUPN
USD
01.05.2026 19:59
47,85 USD
-0,15 USD
-0,31 %
XLON: London
London
0LB2.L
USD
01.05.2026 13:34
47,32 USD
-0,68 USD
-1,42 %
XDUS: Düsseldorf
Düsseldorf
SPIRSD89.DUSB
EUR
30.04.2026 06:10
41,00 EUR
-
XDQU: Quotrix
Quotrix
SPIRSD89.DUSD
EUR
30.04.2026 05:27
41,40 EUR
-
Flottant et Liquidité des Actions
Flottant Libre 94,56 %
Actions en Flottant 54,45 M
Actions en Circulation 57,58 M
Fonds investis

Les fonds suivants ont investi dans SUPERNUS PHARMACEUTICALS INC :

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millions
49,89
Part (%)
0,12 %
Profil de l'entreprise pour SUPERNUS PHARMACEUTICALS INC Action
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Données de l'entreprise

Nom SUPERNUS PHARMACEUTICALS INC
Société Supernus Pharmaceuticals, Inc.
Symbole SUPN
Site web https://www.supernus.com
Marché d'origine XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A1JX3U
ISIN US8684591089
Type de titre Action
Secteur Healthcare
Industrie Medical - Pharmaceuticals
PDG Jack A. Khattar
Capitalisation boursière 3 Mrd.
Pays États-Unis d'Amérique
Devise USD
Employés 0,7 T
Adresse 9715 Key West Avenue, 20850 Rockville
Date d'introduction en bourse 2018-01-29
Dividendes de 'SUPERNUS PHARMACEUTICALS INC'
Date ex-dividende Dividende par action
15.03.2022 0,29 USD

Symboles boursiers

Nom Symbole
Düsseldorf SPIRSD89.DUSB
Frankfurt S49.F
London 0LB2.L
NASDAQ SUPN
Quotrix SPIRSD89.DUSD
Autres actions
Les investisseurs qui détiennent SUPERNUS PHARMACEUTICALS INC ont également les actions suivantes dans leur portefeuille :
AGIF-A.GL.ART.INTEL.AT EO
AGIF-A.GL.ART.INTEL.AT EO Fonds
AMGEN INC
AMGEN INC Action
AUTODESK INC
AUTODESK INC Action
CIELO WASTE SOLUTIONS
CIELO WASTE SOLUTIONS Action
CISCO SYSTEMS INC
CISCO SYSTEMS INC Action
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Action
DEXCO INC
DEXCO INC Action
INTEL CORP
INTEL CORP Action
INTUITIVE SURGICAL INC
INTUITIVE SURGICAL INC Action
KoKo Petroleum Inc.
KoKo Petroleum Inc. Action
MICROSOFT CORP
MICROSOFT CORP Action
UNFI
UNFI Crypto
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Action
YEXT INC        DL 0,001
YEXT INC DL 0,001 Action